Many vision diseases that lead to blindness share one thing in common, and that is the breakdown of the retina. It would be great to stop that from happening. It would be even better to understand retinal cell development as a way to find the best cell type for retina transplantation. Projects at University of Pennsylvania and the Scripps Research Institute are studying these things and here is what they found.
Cell Subgroups
Unfortunately, transplanting healthy photoreceptor cells doesn’t work because very few of the donated cells successfully connect to restore vision. It would be great if there was a way to make photoreceptor transplantation work so that vision could be restored.
Researchers in the lab of Katherine Uyhazi, MD, PhD, an assistant professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, found three different development stages of photoreceptor cells in mice that may have similar cell groups in humans. They hope to learn which cell population is most capable of forming connections from the eye to the brain. Their findings may help to identify which cells are able to survive transplantation, form connections and lead to improved outcomes.
Current treatment for retinal disease work to slow or stop vision loss, but they don’t reverse it or replace damaged cells. Cell-based therapies could reverse vision loss or replace damaged cells. Retinal development happens in waves, so, there is a mix of retinal development cell stages at any given age. By using single cell RNA sequencing, first author Joseph Yano, a PhD candidate in Uyhazi’s lab, identified three states of developing photoreceptor cells: early, mid, and late. Researchers showed that similar populations may exist in cells from human retinal organoids. These are three-dimensional lab-grown structures that copy aspects of the human eye.
Scientist in Uyhazi’s lab are working on ways to isolate and transplant each of the cell states in the retina. Early cells are like stem cells and might be better able to survive transplantation. Late cells are more like retinal cells that respond to light. As they continue their experiments with mice, they hope to find the stage of cells that are “just right” to help fix the retina.
Molecules for the Eye
While scientist know about the structural changes that occur when the retina breaks down, what they don’t understand are the molecular signals that influence how the retina deals with disease.
That’s where research comes in. Scientists at Scripps Research Institute, in collaboration with UC San Diego and the Lowy Medical Research Institute, found a molecule called erucamide that plays a role in how cells communicate in the retina. They found that erucamide levels drop as photoreceptors die and restoring this molecule acrtivates cellular responses that support retina stability. This suggests that erucamide may be a part of the retina’s. protective response. This could lead to a new way to slow the progression of diseases that lead to vision loss.
“The retina doesn’t simply deteriorate; in fact, it actively responds to injury,” says senior author Martin Friedlander, a professor at Scripps Research. “Our work identifies erucamide as a signaling molecule that helps coordinate that response.”
The retina relies on communication among the neurons, glial cells, blood vessels and immune cells. This is known as the neurovascular unit and it keeps the visual tissue working. In diseases such as diabetic retinopathy, retinitis pigmentosa and age-related macular degeneration this coordination breaks down, photoreceptors die and vision fades.
This research builds on earlier observations from Friedlander’s lab that transplanted stem cell-derived retinal cells could slow deterioration long after the cells disappeared. This suggests that the cells were releasing protective signals that lasted longer than the cells themselves. This led to researchers to look for the specific molecules responsible for those signals.
While fat-like substances known as lipids act as signaling molecules in the body, they haven’t been studied in the context of retinal disease. Researchers used mass spectrometry-based metabolomics, a system for measuring many small molecules in tissues at once, to look for molecules that changed as disease advanced.
The molecule that stood out was erucamide. Its levels fell as photoreceptors deteriorated. This suggests that erucamide might influence how eye tissue responds rather than simply changing as result of disease.
Next, scientists wanted to see if restoring erucamide could affect the retinal degeneration. They reintroduced erucamide by way of porous silicon nanoparticles, which are tiny, engineered delivery mechanisms designed to release molecules in a controlled manner. The nanoparticles helped to keep the molecule stable and evenly distributed, because it doesn’t dissolve well in water and can form clumps when injected.
They found that erucamide activated a group of immune cells in the retina called CD11b⁺ myeloid cells. These cells react to injury and support tissue health. Researchers also identified a protein called TMEM19 that erucamide binds to. By reducing TMEM19 levels, researchers prevented the activation of myeloid cells and blocked erucamide’s protective effects.
Of course, there’s more. Once the myeloid cells were stimulated, they released signals linked to neurovascular stabilization, helping support both the nerve cells and blood vessels that nourish them. While this wasn’t a reversal of retinal damage, it did slow features of degeneration by helping preserve the structure and function of the remaining tissue. These findings suggest that erucamide works by influencing the surrounding environment. Still, additional studies are needed. Researchers plan to focus on the molecule’s signaling in various retinal diseases and if targeting this pathway is beneficial.
Researchers at the University of Pennsylvania are studying ways to make photoreceptor transplantation work so that it can be utilized for those who have retinal disease. Researchers at Scripps Research Institute want to see if the molecule erucamide could help protect the retina when diseases occur. While more work needs to be done, research projects like these demonstrate that there may be multiple ways to treat retinal diseases and restore vision, not just maintain the vision that remains.
Sources:
https://www.pennmedicine.org/news/cell-subgroups-could-spur-retinal-cell-transplant-success
